Gilead Sciences Inc buy ValueFreak
Start price
27.07.11
/
50%
€14.68
Target price
26.01.12
€18.00
Performance (%)
25.99%
End price
26.01.12
€18.50
Summary
This prediction ended on 26.01.12 with a price of €18.50. The prediction had a final performance of 25.99%. ValueFreak has a follow-up prediction for Gilead Sciences Inc where he still thinks Gilead Sciences Inc is a Buy. ValueFreak has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Gilead Sciences Inc | -2.068% | -2.068% | -17.502% | 16.945% |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
According to ValueFreak what are the pros and cons of Gilead Sciences Inc for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Very high dividend yield expected
Top Rating
Very positive Cash Flow expected
High Investments for future growth
Valuable balance sheet
Normal challenges to pay loans and raise capital
ROE higher than 15% per year
Very capable Management
Very good company culture
Leading role in innovation
Strong uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Market Leader or Top 3
Very small cyclical dependencies
Well known brand
Very Future proof/growth oriented business model
Cons
Comments by ValueFreak for this prediction
In the thread Gilead Sciences Inc diskutieren
Gesunde Cashflows
Gilead hat gerade einen Umsatzanstieg von 11% gegenüber Vorjahr veröffentlicht. Obwohl die Aktie während der Börsensitzung nachgegeben hat und offenbar auch nachbörslich keiner von den Zahlen beeindruckt ist, werte ich das Ergebnis als kontinuierlichen Geschäftserfolg und steige mit einer Empfehlung ein.
Quelle: Quartalsergebnis 2011Q2
(Laufzeit überschritten)
Current prediction by ValueFreak for Gilead Sciences Inc
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.48
30.09.16
30.09.16
€98.00
08.09.26
08.09.26
11.57%
29.04.24
29.04.24
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Stopped prediction by ValueFreak for Gilead Sciences Inc
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€13.88
21.11.10
21.11.10
€22.50
23.05.11
23.05.11
4.14%
23.05.11
23.05.11
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€15.52
25.04.10
25.04.10
€22.29
25.10.10
25.10.10
-9.83%
25.10.10
25.10.10
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued